Content

Genome Editing: From Bench to Bedside

Part of the BTEC Fall 2019 Seminar Series

Daniel MacLeod, Ph.D.
Director of Cell Therapy Discovery, Precision BioSciences, Inc.

Seminar description

Genome editing technologies allow us to rethink our approach to a broad array of serious challenges faced by the world today. We now have the ability to precisely edit the DNA of a living organism, opening up the possibility of correcting genetic problems at their source. At Precision BioSciences, we utilize a proprietary genome editing method we call ARCUS combined with a team made up of some of the leading minds and pioneers in genome editing in an effort to overcome cancers, cure genetic diseases, and enable the development of safer, more productive food sources. The FDA recently accepted our investigational new drug application for our first gene-edited allogeneic CAR T cell candidate targeting CD19, PBCAR0191, and on April 15, 2019, we initiated dosing of PBCAR0191 in our Phase 1/2a clinical trial. This represents a major step forward in translating the science behind genome editing into novel therapeutics for patients in need.